Gene targeting techniques for Huntington's disease

被引：18

作者：

Fields, Eric ^{[1
]}

Vaughan, Erik ^{[1
]}

Tripu, Deepika ^{[1
]}

Lim, Isabelle ^{[1
]}

Shrout, Katherine ^{[1
]}

Conway, Jessica ^{[1
]}

Salib, Nicole ^{[1
]}

Lee, Yubin ^{[1
]}

Dhamsania, Akash ^{[1
]}

Jacobsen, Michael ^{[1
]}

Woo, Ashley ^{[1
]}

Xue, Huijing ^{[2
]}

Cao, Kan ^{[1
,2
]}

机构：

[1] Univ Maryland, Gemstone Honors Program, College Pk, MD 20742 USA

[2] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA

来源：

AGEING RESEARCH REVIEWS | 2021年 / 70卷

关键词：

Huntington's disease; Allele-specific targeting; Prime editing; SNPs; MUTANT HUNTINGTIN; CAG REPEAT; GUT MICROBIOTA; MOUSE MODEL; RNA; MECHANISMS; THERAPY; PHOSPHORYLATION; INACTIVATION; CILIOGENESIS;

D O I：

10.1016/j.arr.2021.101385

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Huntington's disease (HD) is an autosomal neurodegenerative disorder caused by extended trinucleotide CAG repetition in the HTT gene. Wild-type huntingtin protein (HTT) is essential, involved in a variety of crucial cellular functions such as vesicle transportation, cell division, transcription regulation, autophagy, and tissue maintenance. The mutant HTT (mHTT) proteins in the body interfere with HTT's normal cellular functions and cause additional detrimental effects. In this review, we discuss multiple approaches targeting DNA and RNA to reduce mHTT expression. These approaches are categorized into non-allele-specific silencing and allele-specificsilencing using Single Nucleotide Polymorphisms (SNPs) and haplogroup analysis. Additionally, this review discusses a potential application of recent CRISPR prime editing technology in targeting HD.

引用

页数：8

共 50 条

[31] Targeting Mitochondrial Network Disorganization is Protective in C. elegans Models of Huntington's Disease
Machiela, Emily
Rudich, Paige D.
Traa, Annika
Anglas, Ulrich
Soo, Sonja K.
Senchuk, Megan M.
Raamsdonk, Jeremy M. Van
AGING AND DISEASE, 2021, 12 (07): : 1753 - 1772
[32] A New Drug Design Targeting the Adenosinergic System for Huntington's Disease
Huang, Nai-Kuei
Lin, Jung-Hsin
Lin, Jiun-Tsai
Lin, Chia-I
Liu, Eric Minwei
Lin, Chun-Jung
Chen, Wan-Ping
Shen, Yuh-Chiang
Chen, Hui-Mei
Chen, Jhih-Bin
Lai, Hsing-Lin
Yang, Chieh-Wen
Chiang, Ming-Chang
Wu, Yu-Shuo
Chang, Chen
Chen, Jiang-Fan
Fang, Jim-Min
Lin, Yun-Lian
Chern, Yijuang
PLOS ONE, 2011, 6 (06):
[33] Endoplasmic reticulum stress: The cause and solution to Huntington's disease?
Jiang, Yuwei
Chadwick, Sarah R.
Lajoie, Patrick
BRAIN RESEARCH, 2016, 1648 : 650 - 657
[34] MicroRNAs in Huntington's Disease: Diagnostic Biomarkers or Therapeutic Agents?
Dong, Xiaoyu
Cong, Shuyan
FRONTIERS IN CELLULAR NEUROSCIENCE, 2021, 15
[35] Advances in gene and cellular therapeutic approaches for Huntington's disease
Piao, Xuejiao
Li, Dan
Liu, Hui
Guo, Qing
Yu, Yang
PROTEIN & CELL, 2024,
[36] Latest advances on new promising molecular-based therapeutic approaches for Huntington's disease
Cheng, Yangfan
Zhang, Sirui
Shang, Huifang
JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE, 2024, 12 (02) : 134 - 147
[37] Combination of stem cell and gene therapy ameliorates symptoms in Huntington's disease mice
Cho, In Ki
Hunter, Carissa Emerson
Ye, Sarah
Pongos, Alvince Learnz
Chan, Anthony Wing Sang
NPJ REGENERATIVE MEDICINE, 2019, 4 (1)
[38] Protein aggregates in Huntington's disease
Arrasate, Montserrat
Finkbeiner, Steven
EXPERIMENTAL NEUROLOGY, 2012, 238 (01) : 1 - 11
[39] Targeting Huntington’s disease through histone deacetylases
Steven G. Gray
Clinical Epigenetics, 2011, 2 : 257 - 277
[40] Gene-selective treatment approaches for Huntington's disease
Muehlbaeck, A.
Lindenberg, K. S.
Saft, C.
Priller, J.
Landwehrmeyer, G. B.
NERVENARZT, 2020, 91 (04): : 303 - 311

← 1 2 3 4 5 →